Generic Name and Formulations:
Dutasteride 0.5mg; caps.
Indications for AVODART:
BPH, as monotherapy to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery; or in combination with tamsulosin. Limitation of use: not approved for preventing prostate cancer.
Swallow whole. Monotherapy: 0.5mg once daily. Combination therapy: 0.5mg once daily with tamsulosin 0.4mg once daily.
Not for use in children or women. Pregnant women and those of childbearing potential should avoid handling caps.
Increased risk of high-grade prostate cancer. Monitor prostate specific antigen (PSA) values (establish new baseline PSA after at least 3months of treatment); double PSA levels to compare with normal values. Rule out prostate cancer and other urological disorders prior to treatment. Hepatic dysfunction. Avoid donating blood until at least 6months after last dose.
May be potentiated by CYP3A4/5 inhibitors (eg, ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, ciprofloxacin); caution.
Type I and II 5 alpha-reductase inhibitor.
Impotence, decreased libido, ejaculation disorder, gynecomastia, dizziness (with tamsulosin).
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma
- Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|